Rivaroxaban

32 trials 18 recruiting BHaematology

Filter these 32 trials by condition, phase, country and more.

Open in Search →

32 Registered trials

18 Recruiting

10 Completed trials

28 Sponsors

18 Countries

Phase III

Phase II

Phase IV

Phase III: 9 Phase II/III: 1 Phase II: 4 Phase III/IV: 3 Phase IV: 15

Oversight events:

3 temporary halts 1 unexpected event 5 corrective measures across 3 trials

View oversight register →

Indications tested

Atrial fibrillation 7 Embolic stroke 1 Acute coronary syndrome 1 Atrial flutter 1 Chronic coronary syndrome 1 Pulmonary embolism 1 Joint stabilisation 1 Aortic valve stenosis 1 Cardiac ablation 1 Ischaemic stroke 1 Aortic stenosis 1 Behcet's syndrome 1

Sponsors using this IMP

Assistance Publique Hopitaux De Paris 2 Hamilton Health Sciences Corporation 2 Insel Gruppe AG 2 Oslo University Hospital HF 2 Rigshospitalet 2 Academisch Ziekenhuis Leiden 1 Amsterdam UMC 1 Amsterdam UMC Stichting 1 Anthos Therapeutics Inc. 1 Bispebjerg Hospital 1 Celgene Corp. 1 Centre Hospitalier De Pau 1

All trials — page 2

32 total

DANNOAC- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study Ended

2022-501912-32-00 Phase IV 1 country Bispebjerg Hospital; Gentofte Hospital
Blood thinners after transcatheter implantation of a new heart valve in patients with aortic stenosis Ended

2023-510211-20-00 Phase III 1 country Oslo University Hospital HF
The Nordic Aortic Valve Intervention Trial 4 (NOTION-4) Ended

2024-518547-38-00 Phase IV 1 country Rigshospitalet
A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is compared to another drug called Rivaroxaban in patients wit… Ended

2023-509066-38-00 Phase II 3 countries Anthos Therapeutics Inc.
COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism Ended

2023-504179-26-00 Phase IV 1 country Royal College Of Surgeons In Ireland
Rivaroxaban sotorasib interaction study Ended

2023-505557-41-00 Phase IV 1 country Stichting Radboud University Medical Center
SHORT RUN AF "Rivaroxaban versus standard of care for patients with excessive atrial ectopy or short atrial runs and high embolism risk" Ended

2024-516374-29-00 Phase III/IV 1 country Assistance Publique Hopitaux De Paris
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial Ended

2024-518736-37-00 Phase IV 2 countries University Of Ottawa Heart Institute

Showing 25–32 of 32 trials

← All drugs A–Z